On 6 Nov 2026, Vimta Labs was priced at ₹496.45, or 27.9× trailing earnings, against an industry P/E of 52.8×, and the shares are 26% below their 52-week high. Sales and net profit grew 8.9% and 17% a year over 3 years, with ROCE of 21% and ROE of 18%. It carries very little debt, and its dividend yield is 0.4%. It is a small-cap company with a market cap of ₹2,219 Cr, ranked 7th of 18 Diagnostics & Research companies by market cap; the shares fell 23% over the past year.
- ₹505.05
- ₹512.00
- ₹490.80
- ₹507.30
- 47.3K
Health check
- ReturnsBehind
−23.3% over a year, better than 1 of 7 peers.
- Price tagCheaper
P/E 27.9 vs industry 52.8.
- GrowthSlow
Sales +8.9%, profit +17.2% a year over 3 years.
- ProfitabilityStrong
ROCE 21.0% vs peer median 18.1%.
- Balance sheetSolid
Practically debt-free, Piotroski 6 of 9.
- Red flagsNone found
No warning signs in the headline numbers.
Small cap
Market sensitivity
Key metrics
- Market cap
- ₹2,219 Cr
- Small cap
- P/E
- 27.9
- Industry 52.8
- Price to book
- 4.52
- Peers 11.99
- Dividend yield
- 0.40%
- ROE
- 17.7%
- Peers 15.1%
- ROCE
- 21.0%
- Peers 18.1%
- Debt to equity
- 0.03
- Debt ₹14 Cr
- EPS (TTM)
- ₹17.79
- Face value ₹2
- OPM (TTM)
- 34.7%
- Net margin 18.6%
- Sales growth
- +10.0%
- Latest quarter vs a year ago
- Profit growth
- +3.5%
- Latest quarter vs a year ago
- Price to sales
- 5.14
- EV/EBITDA 14.2
Strengths and risks
Strengths
- Return on capital employed of 21.0%.
- Practically debt-free.
- P/E of 27.9 against an industry P/E of 52.8.
- Positive operating cash flow in each of the last 4 years.
About Vimta Labs
Vimta Labs Limited provides contract research and testing services in India and internationally. The company offers drug discovery, development, and drug life cycle management support services in the areas of preclinical research, clinical research, and analytical services for biopharmaceutical companies; preclinical research and testing services for medical device companies; and contract research and testing for agrochemical and specialty chemical…
- Headquarters
- Hyderabad
- Employees
- 1,384
- Sector
- Healthcare
- ISIN
- INE579C01029
- Website
- vimta.com
Price range
- Avg volume (3M)
- 1.8 L
- 1-year return
- minus 23.3%
- From 52-week high
- minus 26.5%
Peers · Diagnostics & Research
| Company | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SAILIFESai Life Sciences | 1,785.10 | plus 11.95% | 37,929 | 101.5 | 15.22 | 18.1% | 15.1% | 28.7% | 21.3% | 226.8% | 0.00% | plus 72.7% |
| LALPATHLABDr. Lal Path Labs | 1,970.00 | plus 0.16% | 32,941 | 56.5 | 11.99 | 25.7% | 22.6% | 30.2% | 11.1% | 28.3% | 1.02% | plus 24.7% |
| SYNGENESyngene International | 417.30 | plus 0.77% | 16,772 | 90.3 | 3.46 | 8.3% | 3.9% | 25.7% | 5.4% | −12.0% | 0.30% | minus 36.0% |
| VIJAYAVijaya Diagnostic Centre | 1,468.60 | plus 2.15% | 15,126 | 74.4 | 14.29 | 19.1% | 21.2% | 43.1% | 21.0% | 26.9% | 0.14% | plus 40.2% |
| METROPOLISMetropolis Healthcare | 568.75 | minus 0.39% | 11,803 | 52.8 | 7.17 | 15.7% | 14.6% | 21.7% | 12.7% | 10.0% | 0.35% | plus 12.5% |
| THYROCAREThyrocare Technologies | 493.10 | plus 0.68% | 7,848 | 55.0 | 14.75 | 33.8% | 26.4% | 32.2% | 16.7% | 36.2% | 1.89% | plus 8.3% |
| VIMTALABSVimta Labs | 496.45 | minus 2.14% | 2,219 | 27.9 | 4.52 | 21.0% | 17.7% | 34.7% | 8.9% | 17.2% | 0.40% | minus 23.3% |
| SURAKSHASuraksha Diagnostic | 333.55 | plus 0.68% | 1,737 | 48.5 | 7.07 | 14.7% | 14.1% | 21.8% | 17.7% | 70.3% | 0.15% | plus 2.2% |
| Median of 7 peers | – | 0.68% | 15,126 | 56.5 | 11.99 | 18.1% | 15.1% | 28.7% | 16.7% | 28.3% | 0.30% | 12.5% |
Quarterly results
| ₹ Cr | Sep 25 | Dec 25 | Mar 26 | Jun 26 | Sep 26 |
|---|---|---|---|---|---|
| 102 | 98.6 | 109 | 109 | 112 | |
| 67.6 | 64.4 | 69.9 | 71.8 | 74.1 | |
| 34.2 | 34.2 | 39.4 | 37.3 | 37.9 | |
| 33.6% | 34.7% | 36.0% | 34.2% | 33.8% | |
| 2.7 | 1.8 | 2.8 | 3.8 | 2.9 | |
| 0.4 | 0.2 | 0.3 | 0.2 | 0.4 | |
| 10.2 | 10.9 | 12.8 | 12.5 | 12.9 | |
| – | −1.6 | – | – | – | |
| 26.3 | 23.4 | 29 | 28.3 | 27.5 | |
| 24.2% | 24.8% | 27.3% | 25.7% | 25.1% | |
| 19.9 | 17.6 | 21.1 | 21 | 20.6 | |
| 4.44 | 3.94 | 4.62 | 4.66 | 4.57 |
Profit & loss
- Sales CAGR 3Y
- +8.9%
- Profit CAGR 3Y
- +17.2%
- EPS CAGR 3Y
- +17.7%
- ROE
- 17.7%
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 315 | 289 | 344 | 407 | |
| – | minus 8.4% | +19.2% | +18.4% | |
| 215 | 190 | 218 | 257 | |
| 100 | 98.7 | 126 | 150 | |
| 31.9% | 34.2% | 36.7% | 36.9% | |
| 0.6 | 2.6 | 2.9 | 6.4 | |
| 0.9 | 1.5 | 1.4 | 0.5 | |
| 30.7 | 34.2 | 35.7 | 43.8 | |
| −4.4 | −3 | −3.2 | −8.6 | |
| 65 | 62.5 | 89 | 104 | |
| 25.9% | 21.9% | 25.0% | 25.4% | |
| 48.2 | 41 | 67.3 | 77.5 | |
| – | minus 14.9% | +64.2% | +15.1% | |
| 10.68 | 9.12 | 14.93 | 17.40 |
Forecast
Balance sheet
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 4.4 | 4.4 | 4.4 | 8.9 | |
| 277 | 310 | 374 | 448 | |
| 15 | 19.2 | 8.5 | 3.3 | |
| 65.6 | 61.2 | 79.2 | 102 | |
| 362 | 394 | 467 | 562 | |
| 172 | 217 | 262 | 318 | |
| 14.7 | 60.3 | 38.7 | 18.3 | |
| 3.1 | 2.8 | 2.4 | 7.6 | |
| 39.6 | 25.6 | 32.7 | 66.9 | |
| 133 | 89 | 130 | 151 | |
| 362 | 394 | 467 | 562 |
Cash flow
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 87.9 | 60.9 | 94.1 | 147 | |
| −57.3 | −76 | −75.5 | −130 | |
| −11 | −1.9 | −16.1 | −10.4 | |
| 19.7 | −17.1 | 2.4 | 7.1 | |
| −49.8 | −76.6 | −79.5 | −99.8 | |
| 38.1 | −15.7 | 14.6 | 47.3 | |
| −4.4 | −4.4 | −4.4 | −4.5 |
Shareholding pattern
- Promoters35.64%
- Public64.36%
| Quarter | Split | Promoters | Public | Promoter change |
|---|---|---|---|---|
| 30 Sep 2026 | 35.64% | 64.36% | minus 0.03 | |
| 30 Jun 2026 | 35.67% | 64.33% | minus 0.18 | |
| 31 Mar 2026 | 35.85% | 64.15% | minus 0.05 | |
| 31 Dec 2025 | 35.90% | 64.10% | minus 0.09 | |
| 30 Sep 2025 | 35.99% | 64.01% | – |
Major shareholders
Filings & events
News
No recent news coverage found.